Clottable fibrinogen free factor VIII and albumin product and process
US4027013A · kind A · utility
28Cited by
0References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 22, 1976 |
| Grant date | May 31, 1977 |
| Priority date | — |
| Expiry date | Jan 22, 1996 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/83
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lyophilizable, clottable fibrinogen free, Factor VIII is produced on a commercial scale from a fibrinogen containing Factor VIII concentrate by sequentially, precipitating a major portion of the clottable fibrinogen by the addition of an ethylene oxide-polyoxypropylene block copolymer, clotting the remainder of the clottable fibrinogen by the addition of a small amount of a thrombin mimetic enzyme which does not decrease the potency of the Factor VIII, and adding human albumin to the resultant clottable fibrinogen free Factor VIII to stabilize its potency during lyophilization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.